CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Targeting TMED4 enhances CD8(+) T cell function and CAR T cell efficacy in solid tumors through the IRE1α-autophagy axis.
Targeting TMED4 enhances CD8(+) T cell function and CAR T cell efficacy in solid tumors through the IRE1α-autophagy axis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
内质网应激(ERS)和自噬可调节肿瘤浸润T细胞功能及耗竭,但相关机制尚不清楚。本研究发现,ERS相关跨膜蛋白TMED4(跨膜emp24结构域蛋白4)是调节CD8⁺ T细胞抗肿瘤免疫的关键因子。T细胞中敲除Tmed4可通过促进CD8⁺ T细胞增殖、浸润及杀伤能力,同时减少终末耗竭,增强抗肿瘤应答。
从机制上看,Tmed4缺失使肌醇需求酶1(IRE1)-X盒结合蛋白1(XBP1)轴过度活化,并以IRE1依赖方式诱导自噬通量。遗传敲除Ern1(IRE1)或Becn1(Beclin1)会削弱Tmed4缺失带来的抗肿瘤效应,凸显ERS和自噬对CD8⁺ T细胞功能的作用。
此外,Tmed4缺失的CAR-T(CAR-T)细胞抗肿瘤免疫能力增强。采用反义寡核苷酸药理性抑制Tmed4,也能增强CD8⁺ T细胞介导的肿瘤控制。
总之,本研究揭示TMED4通过IRE1驱动的自噬调控CD8⁺ T细胞效应功能并限制其终末耗竭,确立TMED4为提高CAR-T 疗效的潜在免疫治疗靶点。
Endoplasmic reticulum stress (ERS) and autophagy regulate tumor-infiltrating T cell function and exhaustion, but the underlying mechanisms remain unclear.
Here, we identified the ERS-related transmembrane protein TMED4 (transmembrane emp24 domain-containing 4) as a critical regulator of CD8 + T cell antitumor immunity. Tmed4 deletion in T cells enhanced antitumor responses by promoting CD8 + T proliferation, infiltration, and killing capacity, while reducing terminal exhaustion.
Mechanistically, Tmed4 deficiency hyperactivated the inositol-requiring enzyme 1 (IRE1 )-X-box binding protein 1 (XBP1) axis and induced autophagy flux in an IRE1 -dependent manner. Genetic deletion of Ern1 (IRE1 ) or Becn1 (Beclin1) impaired the antitumor effects of Tmed4 deficiency, underscoring the role of ERS and autophagy in CD8 + T cell function.
Moreover, Tmed4 -deficient chimeric antigen receptor T cells (CAR T cells) displayed improved antitumor immunity. Pharmacological inhibition of Tmed4 using antisense oligonucleotide also enhanced CD8 + T cell-mediated tumor control. In summary, our study reveals that TMED4 governs CD8 + T cell effector function and limits terminal exhaustion through IRE1 -driven autophagy, establishing TMED4 as a promising immunotherapeutic target for improving CAR T cell efficacy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。